These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 26618379)

  • 1. Efficacy and Safety of Oral Alendronate Treatment in Children and Adolescents with Osteoporosis.
    Unal E; Abaci A; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-528. PubMed ID: 38742779
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.
    Unal E; Abaci A; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-8. PubMed ID: 16759038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
    Wright E; Schofield PT; Molokhia M
    BMJ Open; 2015 Dec; 5(12):e007133. PubMed ID: 26644118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal events and association with initiation of treatment for osteoporosis.
    Modi A; Siris ES; Tang J; Sajjan S; Sen SS
    Clinicoecon Outcomes Res; 2015; 7():603-13. PubMed ID: 26648746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis.
    Zhou M; Zheng Y; Li J; Wu J; Xu W; Cui L; Yao W; Liu Y
    Exp Ther Med; 2016 Jan; 11(1):289-296. PubMed ID: 26889256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data.
    Cho PG; Ji GY; Shin DA; Ha Y; Yoon DH; Kim KN
    Eur Spine J; 2017 Mar; 26(3):691-697. PubMed ID: 26661639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts.
    Ye Y; Lv X; Wang MH; Zhu J; Chen SQ; Jiang CY; Fu GS
    J Pharmacol Sci; 2015 Dec; 129(4):205-9. PubMed ID: 26627555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smart Strategies to Overcome Drug Delivery Challenges in the Musculoskeletal System.
    Vorrius B; Qiao Z; Ge J; Chen Q
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alendronate combined with local radiotherapy on serum Akt/GSK3β and bone metabolism levels in patients with bone metastases from primary liver cancer.
    Chen L; Zhu W; Zhu S; Ding Q
    Am J Transl Res; 2022; 14(9):6669-6677. PubMed ID: 36247307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence of alendronate treatment for osteoporosis].
    Harada A
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():337-43. PubMed ID: 18161127
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.
    Martín Siguero A; Áreas Del Águila VL; Franco Sereno MT; Fernández Marchante AI; Pérez Serrano R; Encinas Barrios C
    Farm Hosp; 2015 Nov; 39(6):350-4. PubMed ID: 26618379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population.
    Dominguez-Bartmess SN; Tandberg D; Cheema AM; Szalay EA
    J Bone Joint Surg Am; 2012 May; 94(10):e62. PubMed ID: 22617928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.